MX2019012116A - Agentes antifungicos utilizados en combinacion. - Google Patents

Agentes antifungicos utilizados en combinacion.

Info

Publication number
MX2019012116A
MX2019012116A MX2019012116A MX2019012116A MX2019012116A MX 2019012116 A MX2019012116 A MX 2019012116A MX 2019012116 A MX2019012116 A MX 2019012116A MX 2019012116 A MX2019012116 A MX 2019012116A MX 2019012116 A MX2019012116 A MX 2019012116A
Authority
MX
Mexico
Prior art keywords
combination
antifungal
antifungal agents
agents used
relates
Prior art date
Application number
MX2019012116A
Other languages
English (en)
Spanish (es)
Inventor
A Angulo Gonzalez David
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of MX2019012116A publication Critical patent/MX2019012116A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MX2019012116A 2017-04-10 2018-04-04 Agentes antifungicos utilizados en combinacion. MX2019012116A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483647P 2017-04-10 2017-04-10
PCT/US2018/026088 WO2018191077A1 (en) 2017-04-10 2018-04-04 Antifungal agents used in combination

Publications (1)

Publication Number Publication Date
MX2019012116A true MX2019012116A (es) 2019-11-21

Family

ID=62063223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012116A MX2019012116A (es) 2017-04-10 2018-04-04 Agentes antifungicos utilizados en combinacion.

Country Status (13)

Country Link
US (2) US11110102B2 (cg-RX-API-DMAC7.html)
EP (1) EP3609539A1 (cg-RX-API-DMAC7.html)
JP (2) JP7263313B2 (cg-RX-API-DMAC7.html)
KR (1) KR102683355B1 (cg-RX-API-DMAC7.html)
CN (1) CN110769854B (cg-RX-API-DMAC7.html)
AR (1) AR113221A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018253031B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059225A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992413A1 (cg-RX-API-DMAC7.html)
MA (1) MA49889A (cg-RX-API-DMAC7.html)
MX (1) MX2019012116A (cg-RX-API-DMAC7.html)
TW (1) TWI806861B (cg-RX-API-DMAC7.html)
WO (1) WO2018191077A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3661503T3 (pl) * 2017-08-04 2023-01-09 Scynexis, Inc. Środki przeciwgrzybicze o zwiększonej aktywności przy kwasowym odczynie ph
AU2020228036B2 (en) * 2019-02-27 2025-08-07 Scynexis, Inc. Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
WO2010019204A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
BRPI0912074B1 (pt) * 2008-08-12 2021-08-03 Merck Sharp & Dohme Corp Composto e composição farmacêutica
PL3221308T3 (pl) * 2014-11-21 2019-03-29 F2G Limited Środki przeciwgrzybicze
PT3247711T (pt) 2015-01-19 2022-05-16 Scynexis Inc Novos sais e polimorfos de scy-078

Also Published As

Publication number Publication date
JP7263313B2 (ja) 2023-04-24
WO2018191077A1 (en) 2018-10-18
AR113221A1 (es) 2020-02-19
EP3609539A1 (en) 2020-02-19
CN110769854A (zh) 2020-02-07
CN110769854B (zh) 2023-01-13
KR102683355B1 (ko) 2024-07-10
TW201842915A (zh) 2018-12-16
KR20190133251A (ko) 2019-12-02
US20180325919A1 (en) 2018-11-15
US20220202833A1 (en) 2022-06-30
JP2023030113A (ja) 2023-03-07
AU2018253031B2 (en) 2024-04-11
AU2018253031A1 (en) 2019-10-31
KR20240110109A (ko) 2024-07-12
BR112019021138A2 (pt) 2020-05-12
EA201992413A1 (ru) 2020-03-16
MA49889A (fr) 2020-06-24
TWI806861B (zh) 2023-07-01
JP2020513037A (ja) 2020-04-30
JP7574268B2 (ja) 2024-10-28
CA3059225A1 (en) 2018-10-18
US11110102B2 (en) 2021-09-07

Similar Documents

Publication Publication Date Title
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2021008342A (es) Derivados de pirazol como inhibidores de calicreina plasmatica.
ZA201606320B (en) Human plasma kallikrein inhibitors
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
NZ737004A (en) Triazole agonists of the apj receptor
MY194586A (en) Anti-garp antibody
UY36571A (es) Combinaciones de compuestos activos
UA114528C2 (uk) Комбінації активних сполук, що містять карбоксамідні похідні та засіб біологічної боротьби
PH12018501976A1 (en) Arginase inhibitors and their therapeutic applications
MX2013012123A (es) Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida.
PH12016500668A1 (en) Active compound combinations comprising a (thio)carboxamide derivative and a fungicidal compound
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
PH12016501527B1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
UY36432A (es) Combinaciones de compuestos activos que comprenden un derivado de (tio) carboxamida y compuesto(s) fungicida(s)
CO2017005990A2 (es) Combinaciones de compuestos activos que comprenden (a) una carboxamida de indanilo difluorometil-nicotínico de fórmula (i) y otro compuesto activo como fungicida (b)
UY36447A (es) Combinaciones de compuestos activos
CR20170269A (es) Combinaciones de compuestos activos
ZA202003281B (en) Heterocycle substituted pyridine derivative antifungal agents
MX2023001721A (es) Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer.
EA201992413A1 (ru) Противогрибковые средства, используемые в комбинации
UY37397A (es) Combinaciones de compuestos activos
MX2019003697A (es) Sal de metformina de elafibranor que muestra una actividad doble para el tratamiento de la obesidad asociada a la esteatohepatitis no alcoholica (nash) y a la hipertrigliceridemia.
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
NZ780408A (en) Human plasma kallikrein inhibitors